Cargando…

Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study

BACKGROUND: Dexmedetomidine, an alpha(2)-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extraco...

Descripción completa

Detalles Bibliográficos
Autores principales: Leino, Kari, Hynynen, Markku, Jalonen, Jouko, Salmenperä, Markku, Scheinin, Harry, Aantaa, Riku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123640/
https://www.ncbi.nlm.nih.gov/pubmed/21605394
http://dx.doi.org/10.1186/1471-2253-11-9
_version_ 1782207009751302144
author Leino, Kari
Hynynen, Markku
Jalonen, Jouko
Salmenperä, Markku
Scheinin, Harry
Aantaa, Riku
author_facet Leino, Kari
Hynynen, Markku
Jalonen, Jouko
Salmenperä, Markku
Scheinin, Harry
Aantaa, Riku
author_sort Leino, Kari
collection PubMed
description BACKGROUND: Dexmedetomidine, an alpha(2)-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extracorporeal circulation is a stressful procedure increasing sympathetic nervous system activity which could attenuate renal function due the interrelation of sympathetic nervous system, hemodynamics and renal function. We tested the hypothesis that dexmetomidine would improve kidney function in patients undergoing elective CABG during the first two postoperative days. METHODS: This was a double-blind, randomized, parallel-group study. Patients with normal renal function and scheduled for elective CABG were randomized to placebo or to infusion of dexmedetomidine to achieve a pseudo steady-state plasma concentration of 0.60 ng/ml. The infusion was started after anesthesia induction and continued until 4 h after surgery. The primary endpoint was creatinine clearance. Other variables included urinary creatinine and output, fractional sodium and potassium excretion, urinary potassium, sodium and glucose, serum and urinary osmolality and plasma catecholamine concentrations. The data were analyzed with repeated-measures ANOVA or Cochran-Mantel-Haenszel test. RESULTS: Sixty-six of 87 randomized patients were evaluable for analysis. No significant between-group differences were recorded for any indices of renal function except for a mean 74% increase in urinary output with dexmedetomidine in the first 4 h after insertion of a urinary catheter (p < 0.001). Confidence interval examination revealed that the sample size was large enough for the no-difference statement for creatinine clearance. CONCLUSIONS: Use of intravenous dexmedetomidine did not alter renal function in this cohort of relatively low-risk elective CABG patients but was associated with an increase in urinary output. This study was carried out in 1994-1997 and was thus not registered.
format Online
Article
Text
id pubmed-3123640
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31236402011-06-26 Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study Leino, Kari Hynynen, Markku Jalonen, Jouko Salmenperä, Markku Scheinin, Harry Aantaa, Riku BMC Anesthesiol Research Article BACKGROUND: Dexmedetomidine, an alpha(2)-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extracorporeal circulation is a stressful procedure increasing sympathetic nervous system activity which could attenuate renal function due the interrelation of sympathetic nervous system, hemodynamics and renal function. We tested the hypothesis that dexmetomidine would improve kidney function in patients undergoing elective CABG during the first two postoperative days. METHODS: This was a double-blind, randomized, parallel-group study. Patients with normal renal function and scheduled for elective CABG were randomized to placebo or to infusion of dexmedetomidine to achieve a pseudo steady-state plasma concentration of 0.60 ng/ml. The infusion was started after anesthesia induction and continued until 4 h after surgery. The primary endpoint was creatinine clearance. Other variables included urinary creatinine and output, fractional sodium and potassium excretion, urinary potassium, sodium and glucose, serum and urinary osmolality and plasma catecholamine concentrations. The data were analyzed with repeated-measures ANOVA or Cochran-Mantel-Haenszel test. RESULTS: Sixty-six of 87 randomized patients were evaluable for analysis. No significant between-group differences were recorded for any indices of renal function except for a mean 74% increase in urinary output with dexmedetomidine in the first 4 h after insertion of a urinary catheter (p < 0.001). Confidence interval examination revealed that the sample size was large enough for the no-difference statement for creatinine clearance. CONCLUSIONS: Use of intravenous dexmedetomidine did not alter renal function in this cohort of relatively low-risk elective CABG patients but was associated with an increase in urinary output. This study was carried out in 1994-1997 and was thus not registered. BioMed Central 2011-05-23 /pmc/articles/PMC3123640/ /pubmed/21605394 http://dx.doi.org/10.1186/1471-2253-11-9 Text en Copyright ©2011 Leino et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Leino, Kari
Hynynen, Markku
Jalonen, Jouko
Salmenperä, Markku
Scheinin, Harry
Aantaa, Riku
Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
title Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
title_full Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
title_fullStr Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
title_full_unstemmed Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
title_short Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
title_sort renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123640/
https://www.ncbi.nlm.nih.gov/pubmed/21605394
http://dx.doi.org/10.1186/1471-2253-11-9
work_keys_str_mv AT leinokari renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy
AT hynynenmarkku renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy
AT jalonenjouko renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy
AT salmenperamarkku renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy
AT scheininharry renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy
AT aantaariku renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy